Duale, Ovia & Alex-Adedipe Advises InstaDeep on its Sale to BioNTech

We are delighted to announce that Duale, Ovia & Alex-Adedipe recently advised InstaDeep, a leading global technology company in the field of artificial intelligence and machine learning, on its sale to BioNTech, a next-generation immunotherapy company pioneering novel therapies for cancer and other serious diseases.

Our firm advised in relation to the Nigerian subsidiary of InstaDeep, which is headquartered in London. The transaction is valued at approximately £362 million plus an earn-out of up to approximately £200 million.

We worked closely with the international law firm of CMS (Cameron McKenna Nabarro Olswang LLP) – London office. The team was led by Adeleke Alex-Adedipe and Seye Ayinla, with Simisola Eyisanmi.

This transaction represents a major milestone for both InstaDeep and BioNTech. By combining their expertise and innovative technologies, they will be able to develop groundbreaking solutions for serious diseases.

“We are honored to have been a part of this exciting transaction and to have worked with InstaDeep and BioNTech,” said Adeleke Alex-Adedipe, Partner at Duale, Ovia & Alex-Adedipe. “The collaboration between these two companies will undoubtedly lead to new, innovative therapies that will make a real difference in the lives of people around the world.”

Duale, Ovia & Alex-Adedipe is proud to have advised on this significant transaction and to have played a role in bringing together two leading companies in their respective fields. We look forward to seeing the positive impact that this collaboration will have on the healthcare industry.